Updates

Abcam - Makes US$155m acquisition

May 2012

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

Abcam, an online retailer of research-grade antibodies, has announced the acquisition of Epitomics, an antibody business based in San Francisco for US$155m. This will be half in cash (funded by net cash of £56m, plus a new £20m bank facility) and half in new Abcam shares. Epitomics, whose main operations are in Hangzhou, China, is focused on the manufacture of rabbit monoclonal antibodies. These have been found to perform better than conventional mice antibodies, the big advantage being that they are more specific and will only bind to the desired epitope and nothing else. Epitomics has 3,200 products in its catalogue, which are sold to academic and pharmaceutical research applications while it also produces custom ass ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Coastal Energy - Another Burren Energy in the making?

UMECO

Abcam (September 2020)

Abcam (February 2019)

Abcam (September 2018)

Abcam (May 2018)

Abcam (October 2017)

Abcam - Directors buy shares (May 2017)

Abcam - Supplier of antibodies to scientists enjoys 13-fold eps gains over 11 years! (November 2016)

Abcam (March 2013)

Abcam - Protect profit with stop-loss of 360p (December 2012)

Abcam - Trading "slightly ahead of expectations" (September 2012)

Abcam - Acquisition takes Abcam into new US$6 bn market (December 2011)

Abcam - Results slightly ahead of expectations (September 2011)

Abcam - Acquires US-based firm (July 2011)

Abcam (June 2011)

Abcam (December 2010)

Abcam - Shares now Â£5 above tip price (October 2010)

Abcam - Shares soar after strong trading triggers broker upgrades (September 2010)

Abcam - Supplier of antibodies enjoys three eps upgrades in six months (May 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X